AFFIRM: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

Condition:   Primary Biliary Cholangitis Interventions:   Drug: Seladelpar 10 mg;   Drug: Placebo Sponsor:   CymaBay Therapeutics, Inc. Recruiting

Source: ClinicalTrials.gov - September 25, 2023 Category: Research Source Type: clinical trials